July 24, 2023
The FDA said it does not expect there to be immediate significant impact to the U.S. drug supply stemming from the recent tornado damage at Pfizer’s Rocky Mount, North Carolina facility.
On Friday, the federal agency said it was working closely with the manufacturer to assess the potential scope of challenges related to the July 19 EF3 tornado. The FDA said it didn’t expect immediate impact because there was “redundancy in the supply chain due to other manufacturers” for most of the facility’s products.
“We remain committed to partnering across government, academia, and industry to strengthen and diversify the supply chain and ensure Americans continue to have access to drugs that are high quality, safe and effective,” FDA Commissioner Robert M. Califf, MD, MACC, said in a statement.
Here’s what you need to know:
“These allocation measures could lead to localized supply disruptions depending on contractual relationships for supplies,” the FDA said. “Health care systems that have trouble in obtaining a particular drug should contact their distributor or Pfizer directly.”
Statements from Pfizer and the FDA are available online. HAP continues to monitor the latest emergency management implications from the Pfizer facility damage. HAP members can read a member-only resource focused on the potential preparedness strategies to consider following the storm.
Tags: Emergency Preparedness | Affordable Prescription Drugs
Click on topic below for category-specific news articles.
Support a healthier Pennsylvania.